PMID

Data

Article Title

Organization

Discovery of triazole aminopyrazines as a highly potent and selective series of PI3Kd inhibitors.

Astrazeneca

Imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, substrate-dependent modulators of insulin-degrading enzyme in amyloid-ß hydrolysis.

University of Lille

Synthesis and enzymatic evaluation of novel partially fluorinated thiol dual ACE/NEP inhibitors.

Dipartimento Di Chimica

Designed multiple ligands. An emerging drug discovery paradigm.

Organon Laboratories

Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells.

University Institute of Pathology

Potent and selective non-peptidic inhibitors of endothelin-converting enzyme-1 with sustained duration of action.

Novartis Institute For Biomedical Research

Hydroxamic acid derivatives as potent peptide deformylase inhibitors and antibacterial agents.

F. Hoffmann-La Roche

Design and synthesis of potent, selective inhibitors of endothelin-converting enzyme.

Novartis Pharmaceuticals

Hydroxamic acids as potent inhibitors of endothelin-converting enzyme from human bronchiolar smooth muscle.

Berlex Laboratories

Phosphorus-containing inhibitors of endothelin converting enzyme: effects of the electronic nature of phosphorus on inhibitor potency.

Monsanto

 

Potent non-peptidic dual inhibitors of endothelin-converting enzyme and neutral endopeptidase 24.11

TBA

 

Design and synthesis of phosphinic acids that triply inhibit endothelin converting enzyme, angiotensin converting enzyme and neutral endopeptidase 24.11

TBA

 

Solid phase synthesis of phosphinic acid endothelin converting enzyme inhibitors

TBA

 

Highly potent and selective inhibitors of endothelin converting enzyme

TBA

 

Thiol and hydroxamic acid containing inhibitors of endothelin converting enzyme

TBA

Phosphinic tripeptides as dual angiotensin-converting enzyme C-domain and endothelin-converting enzyme-1 inhibitors.

Cea

 

Optimization of retro-thiorphan for inhibition of endothelin converting enzyme

TBA

Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder. Synthesis and activity of functionalized glutaramides.

Pfizer

Novel, selective indole-based ECE inhibitors: lead optimization via solid-phase and classical synthesis.

Bayer Healthcare

Synthesis and biological activity of potent heterocyclic thiol-based inhibitors of endothelin-converting enzyme-1.

Novartis Institute For Biomedical Research

N-[2-(Indan-1-yl)-3-mercapto-propionyl] amino acids as highly potent inhibitors of the three vasopeptidases (NEP, ACE, ECE): In vitro and In vivo activities.

University of Paris

Synthesis of triazole-Tethered pyrrolidine libraries: novel ECE inhibitors.

F. Hoffmann-La Roche

2-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)- and 2-(2,2-dioxo-1,4-dihydro-2H-2lambda6-benzo[1,2,6]thiadiazin-3-yl)-N-hydroxy-acetamides as potent and selective peptide deformylase inhibitors.

F. Hoffmann-La Roche

Discovery of Cyclic Boronic Acid QPX7728, an Ultrabroad-Spectrum Inhibitor of Serine and Metallo-?-lactamases.

Qpex Biopharma

Synthesis and biological activity of novel potent endothelin-converting enzyme-1 inhibitors.

Novartis Institute For Biomedical Research

Discovery of Fluoromethylketone-Based Peptidomimetics as Covalent ATG4B (Autophagin-1) Inhibitors.

Roche Pharma Research and Early Development

Design and synthesis of potent thiol-based inhibitors of endothelin converting enzyme-1.

Novartis Institute For Biomedical Research

Synthesis of a phostone glycomimetic of the endothelin converting enzyme inhibitor phosphoramidon.

Université

Synthesis of novel substituted pyridines as inhibitors of endothelin converting enzyme-1 (ECE-1).

Warner-Lambert

Highly selective and orally active inhibitors of type IV collagenase (MMP-9 and MMP-2): N-sulfonylamino acid derivatives.

Shionogi

Discovery of TD-0212, an Orally Active Dual Pharmacology AT

Theravance Biopharma Us